273. Infectious Disease Outcomes Project (iDOP): Determining Susceptibility to Antimicrobial Agents
Session: Poster Abstract Session: Antimicrobial Susceptibility Testing
Friday, October 21, 2011: 12:55 PM
Room: Poster Hall B1
Background: iDOP, an ongoing, collaborative Web-based research project (www.iDOPweb.com), documents trends in infectious disease outcomes at a patient-specific level to help institutions benchmark medical resource utilization and provide quality care.

Methods: An IRB-approved, de-identified, HIPAA-compliant database captures electronic data at no cost to participating hospitals. Several reports are available: MIC distribution, most effective drugs per organism, average length of stay (LOS) per patient per organism, and an antibiogram with a full listing of susceptibility data for the organisms and drugs collected by each hospital, which is useful for clinicians in determining which drug will provide the most effective cost/benefit for the patient infected with each organism.

Results: The database includes 139 organisms and 195 drugs. Pilot aggregate data from hospitals enrolled to date comprise 48,208 visits and 45,868 patient, 127,109 laboratory, 227,068 charge, and 32,201 pharmacy records. Ten organisms were identified as contributing to LOS of at least 7 days: Enterobacter aerogenes (n=14.7 days), Enterococcus faecium (n=13.6); Torulopsis glabrata (n=13), Enterococcus faecalis (n=12.9); Candida albicans (n=11.1) Staphylococcus capitis (n=10), Staphylococcus epidermidis (n=9.4), Proteus mirabilis (n=8.4), Pseudomonas aeruginosa (n=8.2), and Morganella (n=7.4). P aeruginosa contributed to 53 patient visits among 52 patients. Isolates showed the greatest susceptibility to amikacin (94.2%, n=674), followed by polymyxin (85%, n=20), piperacillin/tazobactam (82.8%, n=669), cefepime (78.3%, n=747), tobramycin (70.2%, n=671), imipenem (66.2%, n=742), meropenem (64.2%, n=447), gentamicin (62.9%, n=740), levofloxacin (55.3%, n=295), and ciprofloxacin (46.2%, n=675).

Conclusion: The iDOP database identifies pathologic organisms having the most impact at the patient level, allowing hospitals to target select pathogens and known associated infectious disease diagnoses to determine strategies for reducing LOS and cost.


Subject Category: A. Antimicrobial agents and Resistance

John Gums, PharmD, FCCP, University of Florida, Gainesville, FL

Disclosures:

J. Gums, Ortho-McNeil: Investigator, Research support

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.